Haleon has launched as an independent company 100 per cent focused on consumer health, completing its demerger from GSK. Haleon has a world-class portfolio of brands including Panadol, Sensodyne and Centrum, and will continue to develop category leading brands that address real consumer health needs, while focusing on future innovation across its entire portfolio.
With an increased consumer focus on health and wellness, an ageing global population, an emerging middle class in high-growth economies, growing self-care in the face of increased pressure on public healthcare systems and sizeable unmet consumer needs, Haleon has launched at a time when the consumer healthcare market is set for expansion (expected to be at a rate of 3-4 per cent per annum over the medium-term). Haleon expects to deliver medium-term annual organic revenue growth of 4-6 per cent.
Despite huge improvements in medicine, data and technology, everyday health remains elusive for too many people. Haleon aims to change this through a two-pronged approach. First, by working to remove barriers to better everyday health, and second, by aiming to empower 50 million people a year by 2025 to be more included in opportunities for better everyday health.
The brands within the Haleon portfolio have been providing treatment and improving the quality of life for millions of consumers across the globe for decades.
Brian McNamara, Chief Executive Officer, Haleon, said: “This is a significant milestone for Haleon. Guided by our clear purpose and with a world class portfolio of brands that people know and trust, we stand ready to help address consumer needs and make better everyday health more achievable, inclusive and sustainable.
Dave Barrett, Country Manager, Ireland, Haleon, said: “I couldn’t be more delighted to be celebrating this milestone of Haleon becoming an independent company. Our purpose is to ‘deliver better everyday health with humanity’ and as a global leader now 100 per cent focused on improving consumer health, we are dedicated to making better everyday health more achievable, inclusive and sustainable.
In Ireland, Haleon employs over 930 people, including 900 at our manufacturing facility in Dungarvan, Waterford.
This site is one of the largest manufacturing sites in Haleon’s Consumer Health network, producing nine billion Panadol tablets and 131 million tubes of Poligrip for global supply to over 70 markets.
